Tilpisertib is a serine/threonine kinase inhibitor disclosed in patent WO2017007689, designed to modulate aberrant kinase-driven signaling pathways, and is used extensively in cancer biology and signal transduction research to investigate kinase-dependent cell proliferation, survival, and resistance mechanisms, supporting preclinical evaluation of targeted therapeutic strategies.
Molekulargewicht:
593.13
CAS Nummer:
[2065153-41-3]
Formel:
C33H33ClN8O
Target-Kategorie:
Serine/threonin kinase
T39466
T39466
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten